Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group

被引：0

作者：

Sebastiano Mercadante

Paolo Marchetti

Arturo Cuomo

Massimo Mammucari

Augusto Caraceni

机构：

[1] Anesthesia and Intensive Care & Pain Relief and Supportive Care,Molecular and Clinical Medicine Medical Oncology

[2] La sapienza University of Rome,Abdominal Medical Oncology

[3] National Cancer Institute Pascale,Palliative Care, Pain Therapy and Rehabilitation

[4] Primary Care Unit,Pain Relief and Palliative Care Unit

[5] ASL RME,undefined

[6] National Cancer Institute,undefined

[7] La Maddalena Cancer Center,undefined

来源：

Supportive Care in Cancer | 2016年 / 24卷

关键词：

Breakthrough pain; Opioids; Fentanyl; Morphine;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Controversies exist about the definition and epidemiology of breakthrough cancer pain (BTcP), the pharmacological treatment options, drug dosing, and how to select the medications for BTcP among the new fentanyl products. Existing data were critically evaluated to provide recommendations by an expert group. An algorithm to diagnose BTcP should be used followed by a careful assessment. Fentanyl products provide efficacy and rapidity of action to counteract the temporal pattern of BTcP. The doses of opioids used for background pain should guide the choice of the doses of fentanyl products. The choice of fentanyl products should be based on individual clinical conditions.

引用

页码：961 / 968

页数：7

共 49 条

[41]

Webber K(2011)How practical are transmucosal fentanyl products for breakthrough cancer pain? A survey of user opinion BMJ Support Palliat Care 1 349-undefined

[42]

Mercadante S(2014)Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen J Pain 15 602-undefined

[43]

Mercadante S(2014)Patients’ acceptability of different fentanyl products for breakthrough cancer pain Clin Oncol 26 806-undefined

[44]